{
    "clinical_study": {
        "@rank": "45183", 
        "arm_group": [
            {
                "arm_group_label": "1- EDP239", 
                "arm_group_type": "Experimental", 
                "description": "EDP239 given once a day."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 treatment arm will be placebo, dose given once a day."
            }, 
            {
                "arm_group_label": "2- EDP239", 
                "arm_group_type": "Experimental", 
                "description": "EDP239 given once a day."
            }, 
            {
                "arm_group_label": "3-EDP239", 
                "arm_group_type": "Experimental", 
                "description": "EDP239 given once a day."
            }, 
            {
                "arm_group_label": "4-EDP239", 
                "arm_group_type": "Experimental", 
                "description": "EDP239 given once a day."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV\n      gentotype-1 in chronically infected subjects and to further evaluate the safety profile of\n      EDP239."
        }, 
        "brief_title": "Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have chronic genotype-1 hepatitis C virus infection and plasma HCV-RNA\n             \u2265 105 IU/mL at the time of screening.\n\n          -  Subjects must have chronic HCV infection as determined by any of the following:\n\n          -  be anti-HCV (+) for at least 6 months per subject history or medical records\n\n          -  an anti-HCV test, viral load,  or genotype > 6 months ago\n\n          -  In the setting of a recent positive anti-HCV test (< 6 months), liver biopsy\n             demonstrating chronicity\n\n          -  Subjects must have IL-28b genotype \"CC\"\n\n          -  Subjects must weigh at least 50 kg to participate in the study, and must have a body\n             mass index (BMI) within the range of 18 - 36 kg/m2. BMI = Body weight (kg) / [Height\n             (m)]2\n\n        Exclusion Criteria:\n\n          -  Use of other investigational drugs at the time of enrollment, or within 5 half-lives\n             of enrollment, or within 30 days (for small molecules) whichever is longer; or longer\n             if required by local regulations.\n\n          -  Previous treatment, including the use of any investigational agents, for the\n             treatment of HCV infection.\n\n          -  Women of child bearing potential.\n\n          -  Subjects with IL-28b genotype \"CT or TT\".\n\n          -  ALT \u03b3-GT, and AST must be below 5 x the upper limit of normal (ULN).\n\n          -  Serum bilirubin must not exceed ULN.\n\n          -  The PT (INR) must be within normal limits.\n\n          -  If necessary, laboratory testing may be repeated on one occasion (as soon as\n             possible) prior to randomization, to rule out any laboratory error.\n\n          -  Use of drugs that inhibit or induce CYP3A4."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856426", 
            "org_study_id": "CEDP239X2201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1- EDP239", 
                    "2- EDP239", 
                    "3-EDP239", 
                    "4-EDP239"
                ], 
                "intervention_name": "EDP239", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Hepatitis C infected subjects", 
        "lastchanged_date": "December 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33169"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murray", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84123"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60590"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "20099"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hannover", 
                        "country": "Germany", 
                        "zip": "30625"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "50924"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of Single Doses of EDP239 in Hepatitis C Virus (HCV) Infected Subjects", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood will be collected for Hepatitis C viral load at Day 1.", 
            "measure": "Change from baseline Hepatitis C viral load at Day 1", 
            "safety_issue": "No", 
            "time_frame": "baseline, day 1"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856426"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Laboratory and clinical evaluations will be used as safety events", 
                "measure": "Number of participants with adverse events as a measure of safety", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "A viral load drop in excess of 2.5 will be considered a success.", 
                "measure": "Change from baseline in HCV RNA log", 
                "safety_issue": "No", 
                "time_frame": "baseline, Day 1"
            }, 
            {
                "description": "The concentration in plasma parameters of EDP239 will be determined using the actual recorded sampling times and non-compartmental method.", 
                "measure": "Total concentration in plasma of EDP239 in HCV Gentoype 1 infected subjects", 
                "safety_issue": "No", 
                "time_frame": "baseline, day 1"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}